Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiarrhythmic drug |
| gptkbp:approvedBy |
1984 (US)
|
| gptkbp:ATCCode |
C01BC04
|
| gptkbp:brand |
Almarytm
Apocard Tambocor |
| gptkbp:CASNumber |
54143-55-4
|
| gptkbp:category |
antiarrhythmic agents
ether compounds fluoroarenes piperidines |
| gptkbp:contraindication |
second or third degree AV block
structural heart disease history of myocardial infarction |
| gptkbp:discoveredBy |
gptkb:3M_Pharmaceuticals
|
| gptkbp:drugClass |
Class Ic antiarrhythmic
|
| gptkbp:eliminationHalfLife |
12-27 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C17H20F6N2O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Flecainide
|
| gptkbp:interactsWith |
gptkb:verapamil
gptkb:digoxin beta blockers cimetidine quinidine amiodarone |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
sodium channel blocker
|
| gptkbp:metabolism |
liver
|
| gptkbp:overdoseSymptoms |
cardiac arrest
seizures conduction disturbances |
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
C (US) |
| gptkbp:proteinBinding |
40%
|
| gptkbp:PubChem_CID |
3345
3228 DB01195 |
| gptkbp:riskFactor |
QT prolongation
ventricular arrhythmias proarrhythmia |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
dizziness
headache palpitations dyspnea visual disturbances |
| gptkbp:UNII |
U60A215AP0
|
| gptkbp:usedFor |
gptkb:ventricular_tachycardia
paroxysmal supraventricular tachycardia paroxysmal atrial fibrillation paroxysmal atrial flutter treatment of arrhythmias |
| gptkbp:bfsParent |
gptkb:Atrial_Flutter
|
| gptkbp:bfsLayer |
7
|